Andere talen Aditxt, Inc.

Aandelen

ADTX

US0070256047

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 20-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,09 ^USD	+3,98%		+1,46%	-68,48%

20/05	Aditxt, Inc. Rapporteert winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
16/04	Aditxt, Inc. Rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Aditxt, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	20/05
Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules	06/05
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules	03/05
Aditxt, Inc. announced that it expects to receive $4.2 million in funding	03/05
Aditxt, Inc. announced that it expects to receive $150 million in funding	02/05
Aditxt, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04
Appili Therapeutics Signs Definitive Agreement to be acquired by Aditxt, Inc.	03/04
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense	03/04
Appili Therapeutics To be Acquired by Aditxt, Inc.	02/04
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)	02/04
Evofem Biosciences - For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy	08/03
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy	07/03
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023	01/02
Aditxt, Inc. Acquires Proprietary Electroencephalography Brain Monitoring Technologies and Devices, Including NeuroCap and NeuroEEG for Telehealth and Tele-neurology Applications	31/01
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications	30/01
Aditxt, Inc.'s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.'s Proprietary Mitomic Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million	09/01
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules	08/01
Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million	08/01
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules	05/01
Aditxt, Inc. announced that it has received $6.000003 million in funding	04/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Aditxt, Inc.

Aandelen

ADTX

US0070256047

Andere talen

Filters